These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 36439885)
1. Downregulation of SEPTIN5 inhibits prostate cancer progression by increasing CD8 Chang M; He Y; Liu C; Lin R; Huang X; Liang D; Zhang J; Lu Y Int J Biol Sci; 2022; 18(16):6035-6051. PubMed ID: 36439885 [No Abstract] [Full Text] [Related]
2. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259 [TBL] [Abstract][Full Text] [Related]
5. Fan Y; Ge Y; Niu K; Li Y; Qi LW; Zhu H; Ma G Front Immunol; 2024; 15():1364329. PubMed ID: 38698844 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of tumour-infiltrating CD103 Zhou Q; Ou Y; Dai X; Chen X; Wu S; Chen W; Hu M; Yang C; Zhang L; Jiang H Br J Cancer; 2023 Apr; 128(8):1466-1477. PubMed ID: 36759726 [TBL] [Abstract][Full Text] [Related]
7. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
8. GLIS1, Correlated with Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer. Peng Q; Xie T; Wang Y; Ho VW; Teoh JY; Chiu PK; Ng CF Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203661 [TBL] [Abstract][Full Text] [Related]
9. LINC00152 mediates CD8 Ou J; Lei P; Yang Z; Yang M; Luo L; Mo H; Luo G; He J J Mol Histol; 2021 Jun; 52(3):611-620. PubMed ID: 33709190 [TBL] [Abstract][Full Text] [Related]
10. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer. Meng X; Yuan H; Li W; Xiong Z; Dong W; Xiao W; Zhang X IUBMB Life; 2021 Nov; 73(11):1363-1377. PubMed ID: 34549875 [TBL] [Abstract][Full Text] [Related]
11. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling. Xiang P; Jin S; Yang Y; Sheng J; He Q; Song Y; Yu W; Hu S; Jin J Prostate; 2019 Jun; 79(9):1018-1031. PubMed ID: 31018021 [TBL] [Abstract][Full Text] [Related]
12. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer. Zhang X; Wang Y; Ning Y Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181 [TBL] [Abstract][Full Text] [Related]
14. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies. Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684 [TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells. Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817 [TBL] [Abstract][Full Text] [Related]
16. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer. Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062 [TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a poor clinical outcome subtype of primary prostate cancer with Midkine abundance. Zhou Q; Yang C; Mou Z; Wu S; Dai X; Chen X; Ou Y; Zhang L; Sha J; Jiang H Cancer Sci; 2022 Nov; 113(11):3698-3709. PubMed ID: 36018546 [TBL] [Abstract][Full Text] [Related]
18. SNAP25 is a potential prognostic biomarker for prostate cancer. Di L; Gu M; Wu Y; Liu G; Zhang L; Li Y; Zhang W Cancer Cell Int; 2022 Apr; 22(1):144. PubMed ID: 35392903 [TBL] [Abstract][Full Text] [Related]
19. Th17 cells inhibit CD8 Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis the diagnosis, malignant progression and immune infiltrate of ANXA6 in prostate cancer. Huang B; Yang K Genes Genomics; 2023 Sep; 45(9):1197-1209. PubMed ID: 37311953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]